Last reviewed · How we verify
Injectable insulin
Injectable insulin replaces or supplements the body's own insulin to regulate blood glucose by facilitating cellular glucose uptake and storage.
Injectable insulin replaces or supplements the body's own insulin to regulate blood glucose by facilitating cellular glucose uptake and storage. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus (when oral agents are insufficient).
At a glance
| Generic name | Injectable insulin |
|---|---|
| Sponsor | Eli Lilly and Company |
| Drug class | Insulin |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin is a peptide hormone that binds to insulin receptors on muscle, fat, and liver cells, promoting glucose transport into cells and conversion to glycogen or fat for energy storage and metabolism. This lowers blood glucose levels in patients with diabetes who cannot produce sufficient endogenous insulin (type 1 diabetes) or have impaired insulin secretion/action (type 2 diabetes).
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus (when oral agents are insufficient)
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Text Message for Adolescents With Poorly Controlled Type 1 Diabetes (NA)
- Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes (NA)
- ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly (PHASE2)
- IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion (NA)
- Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss (PHASE2)
- Effect of Ambient Temperature on Blood Glucose and Insulin Absorption in Adults With Type 1 Diabetes (NA)
- Exenatide for Smoking Cessation and Prevention of Weight Gain (PHASE2)
- Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Injectable insulin CI brief — competitive landscape report
- Injectable insulin updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI